NCT06391645View on ClinicalTrials.gov

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Nerve Growth Factor

intravenously injection

All Listed Sponsors

collaborator

Beijing University of Chemical Technology

UNKNOWN

collaborator

Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation

UNKNOWN

lead

Beijing Tiantan Hospital

OTHER

NCT06391645 - Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter